Skip to contentO
Oncotelic Therapeutics, Inc.
O
OTLCOncotelic Therapeutics, Inc. Q2 2015 · 10-Q
Revenue—
Net Income-$3.32M-$3.32MN/M vs Q2 2014 EPS Diluted-$0.13-$0.13N/M vs Q2 2014 Operating Income-$3,328,000N/M Operating Cash Flowderived-$2,615,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oncotelic Therapeutics, Inc. · CIK 908259 · Engraved from SEC EDGAR
ended Jun 30, 2015 · filed Aug 6, 2015 · 37 d after period end